1
|
Chiambaretta F, Garraffo R, Elena P, Pouliquen P, Delval L, Rigal D, Dubray C, Goldschmidt P, Tabbara K, Cochereau I. Tear Concentrations of Azithromycin following Topical Administration of a Single Dose of Azithromycin 0.5%, 1.0%, and 1.5% Eyedrops (T1225) in Healthy Volunteers. Eur J Ophthalmol 2018; 18:13-20. [DOI: 10.1177/112067210801800103] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Purpose To evaluate azithromycin tear concentrations after one drop of T1225 0.5%, 1.0%, and 1.5% eyedrops. Methods In this randomized, double-masked study, 91 healthy volunteers received one drop into each eye of T1225 0.5% (n=23), T1225 1.0% (n=38), or T1225 1.5% (n=38). Azithromycin tear concentrations were measured by HPLC-MS at seven time points for 24 hours. Tolerability was evaluated. Results T1225 1.0% and 1.5% had similar pharmacokinetic profiles. After a post-instillation peak (167 to 178 mg/L after 10 minutes), mean concentrations remained above 7 mg/L for 24 hours (except for T1225 1% at H24). A delayed increase of the azithromycin mean tear concentration might be explained by the known late azithromycin release from tissues after storage in cells. Areas under inhibitory curve (AUICs) of T1225 1.0% and 1.5% were higher than AUICs of T1225 0.5% and ranged between 47 and 90. The three T1225 concentrations were safe for the ocular surface. Conclusions Once daily instillation of T1225 1.0% and 1.5% was shown to reach an AUIC markedly above the required threshold for an antibacterial activity against Gram-positive bacteria (25–35). These results suggest that a BID instillation is more likely to ensure antimicrobial activity against Gram-negative bacteria (threshold >100).
Collapse
Affiliation(s)
- F. Chiambaretta
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - R. Garraffo
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - P.P. Elena
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - P. Pouliquen
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - L. Delval
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - D. Rigal
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - C. Dubray
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - P. Goldschmidt
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - K. Tabbara
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - I. Cochereau
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| |
Collapse
|
2
|
Moncharmont P, Makowski C, Dubois C, Rigal D. Traitement immunomodulateur dans l’allo-immunisation fœto-maternelle par anticorps anti-plaquettes anti-HPA-5b : à propos d’un cas sévère. Transfus Clin Biol 2015. [DOI: 10.1016/j.tracli.2015.06.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
3
|
Fattoum J, Cannas G, Malki K, Dubost M, Rigal D, Michallet M. Intérêt de la transfusion de granulocytes dans les infections sévères chez des immunodéprimés suivis pour une hémopathie : expérience du service d’hématologie des Hospices Civils de Lyon sur une période de 5ans. Transfus Clin Biol 2014. [DOI: 10.1016/j.tracli.2014.08.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
4
|
Gilbert M, Paul S, Perrat G, Giannoli C, Pouteil Noble C, Morelon E, Rigal D, Dubois V. Impact of pretransplant human leukocyte antigen-C and -DP antibodies on kidney graft outcome. Transplant Proc 2014; 43:3412-4. [PMID: 22099809 DOI: 10.1016/j.transproceed.2011.09.023] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The aim of our study was to determine whether the presence of specific human leukocyte antigen (HLA)-C and -DP antibodies before transplantation influenced graft outcomes in immunized recipients. Two groups of pretransplant immunized recipients were studied: patients with only classical HLA-A, -B, -DR, -DQ antibodies (n = 176) and those with classical plus HLA-C and/or -DP antibodies (n = 27). Acute antibody-mediated rejection was preferentially associated with the presence of pretransplant anti-HLA-C and -DP antibodies (5/6 cases). In four cases, acute rejection episodes were followed by graft loss within 15 months after transplantation. There was a significant increase in the number of acute rejection episodes especially antibody-mediated acute rejections (P = .036) and in the number of graft losses for immunologic reasons (P < .001) among the group with pretransplant anti-C and -DP antibodies. Pretransplant anti-DP antibodies seemed to be involved more frequently in poor graft outcomes as shown in several recent published cases. We need to investigate their specific role among a larger cohort, taking into account an epitope analysis.
Collapse
Affiliation(s)
- M Gilbert
- Histocompatibility Laboratory, Etablissement Français du Sang Rhône-Alpes, Lyon, France
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Moncharmont P, Rigal D. [Association of red blood cell and platelet allo-antibodies in platelet alloimmunized patients]. Transfus Clin Biol 2014; 21:99-102. [PMID: 24948207 DOI: 10.1016/j.tracli.2014.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2014] [Accepted: 05/14/2014] [Indexed: 10/25/2022]
Abstract
PURPOSE OF THE STUDY Use of matched red blood cell (RBC) concentrates is imperative in patients with RBC allo-antibodies (Abs) and when platelet (PLT) specific allo-Abs are present additional difficulties occur for PLT transfusions. In order to evaluate the prevalence of the PLT and RBC allo-Abs association, a study on patients with PLT specific allo-Acs was performed. This association is not a rare event. PATIENTS AND METHODS In the database of a PLT immunohaematology laboratory, patients with PLT specific allo-Abs were selected and the presence and specificity of RBC allo-Abs was evaluated. RESULTS Six hundred and eighty seven patients (673 females, 14 males) with PLT specific allo-Abs were found. Six hundred and seventy-five patients (98.3%) had PLT specific allo-Abs with only one specificity. Anti-HPA-5b was the most frequent (539 cases). Twenty-nine (4.2%) patients had also RBC allo-Abs, including 27 females (93.1%) and two males. Seventy (58.6%) had RBC allo-Abs with only one specificity, 10 several and two unknown. Among the first, RBC allo-Abs directed against Rhesus blood group antigens were predominant (11 cases [64.7%]). Among the 29 patients with associated PLT and RBC allo-Abs, 15 (51.7%) were 50 or more years old and 14 (48.3%) under 50. CONCLUSION In PLT specific alloimmunized patients, detection of RBC alloimmunization is not a rare event. When RBC and PLT transfusions are required, the supply of matched RBC and PLT concentrates is more difficult.
Collapse
Affiliation(s)
- P Moncharmont
- Laboratoire d'immunologie plaquettaire, Établissement français du sang Rhône-Alpes, site de Lyon Gerland, 1-3, rue du Vercors, 69364 Lyon cedex 07, France.
| | - D Rigal
- Laboratoire d'immunologie plaquettaire, Établissement français du sang Rhône-Alpes, site de Lyon Gerland, 1-3, rue du Vercors, 69364 Lyon cedex 07, France
| |
Collapse
|
6
|
Guinchard E, Bricca P, Monnier S, Rigal D. [Non-invasive fetal RHD genotyping: Validation of the method with 200 patients]. Transfus Clin Biol 2014; 21:1-14. [PMID: 24559796 DOI: 10.1016/j.tracli.2013.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2012] [Accepted: 12/09/2013] [Indexed: 10/25/2022]
Abstract
BACKGROUND Non-invasive fetal RHD genotyping is an important tool to assess the risk of fetuse's hemolytic disease of anti-D allo-immunized pregnant woman by non-invasive method. A method of genotyping has been developed in the laboratory of Lyon-GHE according to Minon's team (J Gynecol Obstet Biol Reprod 2005): exon 4, 5, and 10 are amplified by real time PCR. At first, genotyping results of 200 pregnant women have been compared with RH1 phenotype at birth. The most important parameters of validation have been tested: the sensibility and the specificity; the negative predictive value; the correlation study permitted to define criteria of biological interpretation. The validation of this method permitted to determine critical points and the limits of the method due to the minor amount of fetal DNA in the maternal plasma and existence of many variant forms of the RHD gene. CONCLUSION We worked too in the perspective to the accreditation for our genetic laboratory.
Collapse
Affiliation(s)
- E Guinchard
- EFS Rhône-Alpes, site de Lyon-GHE, 28, rue Doyen-Lepine, 69677 Bron cedex, France.
| | - P Bricca
- EFS Rhône-Alpes, site de Lyon-GHE, 28, rue Doyen-Lepine, 69677 Bron cedex, France
| | - S Monnier
- EFS Rhône-Alpes, site de Lyon-GHE, 28, rue Doyen-Lepine, 69677 Bron cedex, France
| | - D Rigal
- EFS Rhône-Alpes, site de Lyon-Gerland, 1, rue du Vercors, 69007 Lyon, France
| |
Collapse
|
7
|
Hequet O, Le QH, Rodriguez J, Dubost P, Revesz D, Clerc A, Rigal D, Salles G, Coiffier B. Development of model for analysing respective collections of intended hematopoietic stem cells and harvests of unintended mature cells in apheresis for autologous hematopoietic stem cell collection. Transfus Apher Sci 2014; 50:294-302. [PMID: 24462181 DOI: 10.1016/j.transci.2013.12.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Revised: 12/09/2013] [Accepted: 12/17/2013] [Indexed: 11/29/2022]
Abstract
Hematopoietic stem cells (HSCs) required to perform peripheral hematopoietic autologous stem cell transplantation (APBSCT) can be collected by processing several blood volumes (BVs) in leukapheresis sessions. However, this may cause granulocyte harvest in graft and decrease in patient's platelet blood level. Both consequences may induce disturbances in patient. One apheresis team's current purpose is to improve HSC collection by increasing HSC collection and prevent increase in granulocyte and platelet harvests. Before improving HSC collection it seemed important to know more about the way to harvest these types of cells. The purpose of our study was to develop a simple model for analysing respective collections of intended CD34+ cells among HSC (designated here as HSC) and harvests of unintended platelets or granulocytes among mature cells (designated here as mature cells) considering the number of BVs processed and factors likely to influence cell collection or harvest. For this, we processed 1, 2 and 3 BVs in 59 leukapheresis sessions and analysed corresponding collections and harvests with a referent device (COBE Spectra). First we analysed the amounts of HSC collected and mature cells harvested and second the evolution of the respective shares of HSC and mature cells collected or harvested throughout the BV processes. HSC collections and mature cell harvests increased globally (p<0.0001) and their respective shares remained stable throughout the BV processes (p non-significant). We analysed the role of intrinsic (patient's features) and extrinsic (features before starting leukapheresis sessions) factors in collections and harvests, which showed that only pre-leukapheresis blood levels (CD34+cells and platelets) influenced both cell collections and harvests (CD34+cells and platelets) (p<0.001) and shares of HSC collections and mature unintended cells harvests (p<0.001) throughout the BV processes. Altogether, our results suggested that the main factors likely to influence intended HSC collections or unintended mature cell harvests were pre-leukapheresis blood cell levels. Our model was meant to assist apheresis teams in analysing shares of HSC collected and mature cells harvested with new devices or with new types of HSC mobilization.
Collapse
Affiliation(s)
- O Hequet
- Etablissement Français du Sang Rhône Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Benite, France; Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France.
| | - Q H Le
- Hospices Civils de Lyon, Department of Biostatistics, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - J Rodriguez
- Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France
| | - P Dubost
- Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France
| | - D Revesz
- Etablissement Français du Sang Rhône Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Benite, France
| | - A Clerc
- Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France
| | - D Rigal
- Etablissement Français du Sang Rhône Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Benite, France; Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France
| | - G Salles
- Hospices Civils de Lyon, Hematological unit, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - B Coiffier
- Hospices Civils de Lyon, Hematological unit, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| |
Collapse
|
8
|
Paris S, Silvy M, Bailly P, Verdier M, Barlet V, Rigal D, Brès JC. Développement d’une plate-forme automatisée de génotypage érythrocytaire étendu pour les donneurs de sang. Transfus Clin Biol 2013. [DOI: 10.1016/j.tracli.2013.03.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Paris S, Dupont M, Silvy M, Bailly P, Rigal D, Brès JC. Bilan d’activité après deux années d’utilisation d’une puce à ADN dédiée au génotypage érythrocytaire étendu des patients. Transfus Clin Biol 2013. [DOI: 10.1016/j.tracli.2013.03.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Boccoz S, Brès J, Bailly P, Rigal D, Blum L, Marquette C. Validation d’une plateforme totalement automatisée pour le génotypage érythrocytaire étendu. Transfus Clin Biol 2013. [DOI: 10.1016/j.tracli.2013.04.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Paris S, Bertrand G, Kaplan C, Rigal D, Brès JC. Développement de puces à ADN pour le génotypage des antigènes plaquettaires humains HPA-1, -5 et -15. Transfus Clin Biol 2013. [DOI: 10.1016/j.tracli.2013.03.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
12
|
Moncharmont P, Makowski C, Equy V, Andrini P, Rigal D. Occurrence of anti-HPA-5b alloantibodies during intravenous immunoglobulin treatment in an HPA-15b alloimmunised woman: a case report. Transfus Med 2013; 23:202-3. [PMID: 23402651 DOI: 10.1111/tme.12015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2012] [Revised: 10/29/2012] [Accepted: 01/17/2013] [Indexed: 11/27/2022]
|
13
|
Moncharmont P, Rigal D. Prévalence des anticorps antiplaquettes spécifiques chez les receveurs de concentrés plaquettaires avec effet indésirable transfusionnel. Transfus Clin Biol 2012; 19:333-7. [DOI: 10.1016/j.tracli.2012.06.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2012] [Accepted: 06/16/2012] [Indexed: 10/27/2022]
|
14
|
Abstract
The pattern of autoimmune hemolytic anemia has changed significantly these last 15 years. With regard to the diagnosis strategy, the use of gel filtration technique to perform the direct antiglobulin test (DAT) has decreased the number of autoimmune haemolytic anemias with negative tests results. In recent years, autoimmune haemolytic anemia increased in patients receiving purine nucleoside analogues, blood transfusions, solid organ transplantation or hematopoietic stem cells transplantation. These difficult autoimmune haemolytic anemia cases need to use new kinds of treatments. With regard to the treatment, very little progress was made this latter 50 years. The discovery of the efficacy of anti-CD20 antibody in this disease represents a breakthrough. Nowdays, the second-line treatment includes rituximab or splenectomy. Sometimes, the anti-CD20 treatment could be proposed in first-line but some clinical trials are needed.
Collapse
Affiliation(s)
- D Rigal
- Laboratoire d'immunohématologie et service d'hémovigilance, établissement français du sang, 1-3, rue du Vercors, 69007 Lyon, France.
| | | |
Collapse
|
15
|
Desmet C, Le Goff GC, Brès JC, Rigal D, Blum LJ, Marquette CA. Multiplexed immunoassay for the rapid detection of anti-tumor-associated antigens antibodies. Analyst 2011; 136:2918-24. [PMID: 21666912 DOI: 10.1039/c1an15121e] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- C Desmet
- Equipe Génie Enzymatique, Membranes Biomimétiques et Assemblages Supramoléculaires, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, Université Lyon 1-CNRS 5246 ICBMS, Villeurbanne Cedex, France
| | | | | | | | | | | |
Collapse
|
16
|
Hequet O, Le Q, Rigal D, Mekhloufi F, Jaeger S, Sassolas A, Groisne L, Moulin P. The first results demonstrating efficiency and safety of a double-column whole blood method of LDL-apheresis. Transfus Apher Sci 2010; 42:3-10. [DOI: 10.1016/j.transci.2009.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2008] [Accepted: 08/25/2009] [Indexed: 10/20/2022]
|
17
|
Guillot-Chene P, Lebecque S, Rigal D. [Towards an industrial control of the cloning of lymphocytes B human for the manufacturing of monoclonal antibodies stemming from the human repertoire]. Ann Pharm Fr 2009; 67:182-6. [PMID: 19446667 DOI: 10.1016/j.pharma.2009.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2008] [Revised: 01/09/2009] [Accepted: 02/20/2009] [Indexed: 11/17/2022]
Abstract
Monoclonal antibodies (mAbs) are efficient drugs for treating infectious, inflammatory and cancer diseases. Antibodies secreted by human lymphocytes that have been isolated from either peripheral blood or tissues present the definite interest of being part of the physiological or disease-related response to antigens present in the human body. However, attempts to generate hybridomas with human B cells have been largely unsuccessful, and cloning of human B cells has been achieved only via their inefficient immortalization with Epstein Barr Virus (EBV). However, recent progress in our understanding of the molecular mechanisms of polyclonal B cell activation has dramatically increased the capacity to clone human B cells. In particular, activation of human naïve and memory B cells through CD40 or memory B cells only through TLR9 was shown to greatly facilitate their immortalization by EBV. Industrial development based on these observations will soon provide large collections of high affinity human mAbs of every isotype directly selected by the human immune system directed to recognize epitopes relevant for individual patients. Moreover, after CD40 activation, these mAbs will cover the full human repertoire, including the natural auto-immune repertoire. Full characterization of the biological activity of these mAbs will in turn bring useful information for selecting vaccine epitopes. This breakthrough in human B cell cloning opens the way into new areas for therapeutic use of mAbs.
Collapse
|
18
|
Abstract
In Evans syndrome, IgG auto-antibodies (Abs) and/or complement components are frequently detected on red blood cells (RBC) in the direct antiglobulin test (DAT). A 70-year-old man with Evans syndrome diagnosed four years previously presented with a persistent autoimmune haemolytic anaemia, despite immunosuppressive treatment and normalization of platelet count. The RBC allo- and auto-Abs screening and identification were performed by indirect antiglobulin test (IAT) and DAT. In March 2006, no circulating anti-RBC auto-Abs were found in IAT but the DAT was positive with anti-IgG (++), -C3d (weak) and -IgA (++). Follow up for 11 months revealed anti-RBC IgA auto-Abs on five out of six samples. IAT was positive for RBC auto-Abs on three samples. No correlation between the haemoglobin level and the strength of reactivity of IgG and IgA auto-Abs was observed. IgA anti-RBC auto-Abs are present in Evans syndrome. To detect these Abs and characterize their role, DAT procedures should systematically include anti-IgA.
Collapse
Affiliation(s)
- P Moncharmont
- Etablissement français du Sang - Rhône-Alpes, Site de Lyon, Lyon Cedex 07, France.
| | | | | |
Collapse
|
19
|
Foxcroft Z, Campbell K, Merieux Y, Urbaniak S, Brierley M, Rigal D, Ouwehand WH, Metcalfe P. Report on the 13th International Society of Blood Transfusion Platelet Immunology Workshop. Vox Sang 2007; 93:300-5. [PMID: 18070273 DOI: 10.1111/j.1423-0410.2007.00951.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND OBJECTIVES The aim of the 13th International Society of Blood Transfusion Platelet Immunology Workshop was to compare the sensitivity and specificity of the in-house method for the detection of human platelet antigen (HPA) antibodies currently used in participating laboratories with a modified rapid protocol for the monoclonal antibody (mAb) immobilization of platelet antigen (MR-MAIPA) assay. MATERIALS AND METHODS Twenty-eight laboratories from 15 countries participated. A set of four freeze-dried minimum potency reference reagents with known single-specificity HPA antibodies were supplied for testing by titration with both assays and two coded freeze-dried plasma samples were provided for antibody specificity testing. Critical reagents and materials for the MR-MAIPA were provided including lyophilized panel platelets and five capture mAbs. RESULTS Titration of the reference standards showed that the sensitivity of the MR-MAIPA was the same as the in-house methods. The proposed replacement anti-HPA-1a reference reagent 05/106 gave results that did not differ significantly from the current reference reagent 93/710. The results with the two blinded samples showed that in the first sample, 27 out of the 28 laboratories were able to correctly identify the anti-HPA-1a present when using their respective in-house methods, but only 23 correctly identified the antibody when using the rapid MAIPA method. The results from the second sample, which contained multispecificities, showed that only 50% of the participants correctly identified all five antibodies present using their in-house method. The results for the rapid MAIPA were lower, with only 32% identifying all specificities. The variability in the reconstitution of the freeze-dried platelets may have been one of the contributing factors to the poorer results. CONCLUSIONS The sensitivity of the MR-MAIPA compared favourably with that of the in-house methods. Most laboratories were able to identify anti-HPA-1a alone in Sample 1 but more than half of the participants were not able to correctly assign the specificity of all HPA antibodies present in the second sample. The usefulness of the panel of freeze-dried platelets varied considerably between laboratories.
Collapse
Affiliation(s)
- Z Foxcroft
- South African National Blood Service, Johannesburg, South Africa.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
UNLABELLED The HPA-15 platelet (PLT) group was recently described. Severe neonatal thrombocytopenia due to alloimmunization by HPA-15b has very rarely been observed. A 22-year-old mother, gravida 1/para 1, gave birth to a male infant who presented with a severe thrombocytopenia, the PLT count recorded to be 3 x10(9)/L. A few hours after birth, he developed purpura with extensive haematomas but without visceral or intracranial haemorrhage (ICH). Two PLT transfusions were given including one using maternal PLTs. The infant's PLT count was 267 x 10(9)/L on day 6. The maternal platelet group was HPA-15a/a and her infant was HPA-15a/b. Anti-HPA-15b antibodies was found in maternal serum. CONCLUSION HPA-15b maternal alloimmunization may induce severe neonatal thrombocytopenia. In order to establish the frequency of neonatal alloimmune thrombocytopenia (NAIT) due to anti-HPA-15b antibodies, an improved detection method is necessary.
Collapse
MESH Headings
- Adult
- Antigens, CD/blood
- Antigens, CD/immunology
- Antigens, Human Platelet/blood
- Antigens, Human Platelet/immunology
- Blood Group Incompatibility/complications
- Blood Group Incompatibility/diagnosis
- Blood Group Incompatibility/therapy
- Cesarean Section
- Female
- GPI-Linked Proteins
- Humans
- Infant, Newborn
- Male
- Maternal-Fetal Exchange/immunology
- Neoplasm Proteins/blood
- Neoplasm Proteins/immunology
- Platelet Transfusion
- Pregnancy
- Pregnancy Complications, Hematologic/immunology
- Purpura, Thrombocytopenic/etiology
- Thrombocytopenia, Neonatal Alloimmune/diagnosis
- Thrombocytopenia, Neonatal Alloimmune/immunology
- Thrombocytopenia, Neonatal Alloimmune/therapy
Collapse
Affiliation(s)
- P Moncharmont
- French Blood Establishment, Rhône-Alpes Lyon Department, Lyon, France.
| | | | | | | | | | | |
Collapse
|
21
|
Moncharmont P, Vignal M, Merieux Y, Rigal D. [Intravenous human immunoglobulin treatment for neonatal alloimmune thrombocytopenia due to anti-HPA-5b with severe previous history]. Arch Pediatr 2007; 14:1094-6. [PMID: 17590318 DOI: 10.1016/j.arcped.2007.05.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2006] [Accepted: 05/11/2007] [Indexed: 10/23/2022]
Abstract
Fetal and neonatal alloimmune thrombocytopenia due to mothers' anti-HPA-5b alloimmunization has generally a milder clinical presentation compared to anti-HPA-1a alloimmunization. Nevertheless, a case with infant's death probably due to intracranial haemorrhage has been reported. However, if platelet-specific alloimmunized mothers with prior fetal or neonate injury receive intravenous immunoglobulins during pregnancy, thrombocytopenia in heterozygous fetus and neonate may be prevented. Here are reported 2 cases of anti-HPA-5b fetal-maternal alloimmunization, one with prior fetal death, the other with prior severe fetal intracranial haemorrhage, which were successfully treated with intraveinous immunoglobulins alone during a second pregnancy with HPA-5b incompatibility.
Collapse
Affiliation(s)
- P Moncharmont
- Etablissement français du sang, Rhône-Alpes, site de Lyon-Gerland, 1-3, rue du Vercors, 69364 Lyon cedex 07, France.
| | | | | | | |
Collapse
|
22
|
Hequet O, Lienhart A, Jaeger S, Meunier S, Sobas F, Rigal D, Negrier C. Adaptability of protein A-immunoadsorption allows temporary reduction of anti-VIII antibodies and realisation of high-risk haemorrhagic surgery. Transfus Apher Sci 2007; 36:255-8. [PMID: 17569589 DOI: 10.1016/j.transci.2007.04.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
We report the successful treatment by protein A-immunoadsorption (IA) of an hemophilic man with anti-F VIII antibodies (Abs) who needed high-risk bleeding surgery. This patient had developed high levels of anti-F VIII Abs preventing substitution by clotting factor and preventing high-risk bleeding surgery. Because of rebound in Abs levels or complications, IA procedures were modified several times leading to appropriate decrease of anti-F VIII inhibitor Abs allowing bilateral knees surgery. IA procedure is enough adaptable to be modified to prevent complications. Collaboration between clinical, biological, apheresis and surgical teams implied has permitted surgery and prevented life-threatening bleeding complications.
Collapse
Affiliation(s)
- O Hequet
- Centre de Santé, Etablissement Français du Sang, Hôpital Edouard Herriot, Lyon, France.
| | | | | | | | | | | | | |
Collapse
|
23
|
Bonnin N, Viennet A, Nezzar H, Dechelotte P, Barthelemy I, Demeocq F, Gabrillargues J, Campagne D, Rigal D, Bacin F. 448 Rhabdomyosarcome palpébral chez un enfant de deux ans. J Fr Ophtalmol 2007. [DOI: 10.1016/s0181-5512(07)80261-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
24
|
Albertini E, Iraci A, Coulangeon L, Creveaux I, Rigal D, Chiambaretta F. 519 Dystrophie grillagée chez l’enfant : une expression phénotypique évolutive. J Fr Ophtalmol 2007. [DOI: 10.1016/s0181-5512(07)80332-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Eljaafari A, Van Snick J, Voisin A, Cormont F, Farre A, Bienvenu J, Bernaud J, Rigal D, Thomas X. Alloreaction increases or restores CD40, CD54, and/or HLA molecule expression in acute myelogenous leukemia blasts, through secretion of inflammatory cytokines: dominant role for TNFβ, in concert with IFNγ. Leukemia 2006; 20:1992-2001. [PMID: 16990783 DOI: 10.1038/sj.leu.2404375] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We have previously reported that alloreaction can lead to activation of dendritic cells through secretion of inflammatory cytokines. Here, we addressed whether alloreaction-derived cytokines may also lead to acute myelogenous leukemia (AML) blast differentiation. With this aim, supernatant (sn) harvested from major or minor histocompatibility antigen-mismatched mixed lymphocyte reaction (MLR) were used to culture French American Bristish (FAB) type M4 or M5 AML blasts. Our results showed that the secreted factors induced upregulation of CD40, CD54, and/or HLA molecules in AML blasts. Protein fractionation, blockade experiments and exogenous cytokine reconstitution demonstrated the involvement of TNF in the upregulation of CD54, CD40 and HLA-class II molecules, and of IFNgamma in the increase of HLA-class I and class II molecule expression. But, in line of its much higher levels of secretion, TNFbeta, rather than TNFalpha, was likely to play a preponderant role in AML blast differentiation. Moreover TNFbeta and IFNgamma were also likely to be involved in the AML blast differentiation-mediated by HLA-identical donor T-cell alloresponse against recipient AML blasts. In conclusion, we show herein that upon allogeneic reaction, TNFbeta secretion contributes, in concert with IFNgamma, to increase or restore surface molecules involved in AML blast interaction with T cells.
Collapse
Affiliation(s)
- A Eljaafari
- Cell Therapy Research Department, EFS-Rhone-Alpes, Lyon, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Goujon C, Jarrosson-Wuillème L, Bernaud J, Rigal D, Darlix JL, Cimarelli A. With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIVMAC. Gene Ther 2006; 13:991-4. [PMID: 16525481 DOI: 10.1038/sj.gt.3302753] [Citation(s) in RCA: 129] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Modification of dendritic cells (DCs) is a promising avenue for gene therapy purposes, given the versatility and the multiplicity of functions of these cells. In this study, we show that preincubation of monocyte-derived DCs with low amounts of non-infectious virion-like particles derived from the simian immunodeficiency virus (SIV(MAC) VLPs) increases up to 10-fold the efficiency of transduction by HIV-1 lentiviral vectors at low multiplicity of infections yielding up to 90% of transduced cells, in the absence of alterations of DCs behavior. This effect is restricted to DCs and specified by the viral accessory protein Vpx. Thus, preincubation with empty VLPs of SIV(MAC) can be used in transduction protocols to increase the efficacy of HIV-1-mediated modification of DCs.
Collapse
Affiliation(s)
- C Goujon
- INSERM U412, Ecole Normale Supérieure de Lyon, IFR 128 BioSciences Lyon-Gerland, Lyon, France
| | | | | | | | | | | |
Collapse
|
27
|
Dériot JB, Ledoux-Pilon A, Pilon F, Ravel A, Déchelotte P, Rigal D, Chiambaretta F. Tumeur fibreuse solitaire de l’orbite : une cause inhabituelle d’exophtalmie unilatérale. J Fr Ophtalmol 2005; 28:999-1005. [PMID: 16395228 DOI: 10.1016/s0181-5512(05)81130-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND The solitary fibrous tumor (SFT) is a spindle-cell tumor that very rarely involves the orbit. We report a new case that we compare to reports in the literature. CASE A 72-year-old woman presented a conjunctival inflammation of the right eye developing over 5 months with progressive proptosis. Magnetic resonance imaging revealed an extraconal and homogeneous mass, which showed hypointensity on T1-weighted images and hyperintensity on T2-weighted images, without specificity. Histological examination of the lesion removed by anterior orbitotomy confirmed the diagnosis of the SFT of the orbit. The patient was doing well without recurrence after 9 months. DISCUSSION The diagnosis of SFT is histological. It is a mesenchymal tumor. Immunohistochemically, the tumor cells are strongly positive for CD34 and vimentin. CONCLUSION The SFT of the orbit is a very rare and generally benign tumor. It must be immunohistochemically differentiated from other spindle-cell tumors of the orbit. The treatment is a complete surgical excision, and long-term follow-up is necessary because recurrence may appear long after treatment.
Collapse
Affiliation(s)
- J-B Dériot
- Service d'Ophtalmologie, Hôpital Gabriel Monpied, CHU Clermont-Ferrand, 58, rue Montalembert, BP69, 63003 Clermont-Ferrand cedex 1, France
| | | | | | | | | | | | | |
Collapse
|
28
|
Miranda de Carvalho C, Bonnefont-Rebeix C, Rigal D, Chabanne L. "Dendritic cells in different animal species: an overview". ACTA ACUST UNITED AC 2005; 54:85-93. [PMID: 16019158 DOI: 10.1016/j.patbio.2005.04.005] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2005] [Accepted: 04/13/2005] [Indexed: 12/30/2022]
Abstract
The comprehension of the immune system and the role of DC in the pathological diseases may contribute to their use in veterinary medicine in the prevention and treatment of many diseases. Currently, most dendritic cell (DC) research occurs in the human and murine model systems on the generation of cells from the bone marrow or peripheral blood mononuclear cells (PBMC) cultured in vitro. Despite the lack of available immunological reagents such as antibodies and cytokines, analogous cells have been generated and identified in many different species and reviewed in this study.
Collapse
Affiliation(s)
- C Miranda de Carvalho
- Etablissement français du sang, 1-3, rue du Vercors, 69007 Lyon, France; Ecole nationale vétérinaire de Lyon, 1, avenue Bourgelat, 69380 Marcy l'Etoile, France.
| | | | | | | |
Collapse
|
29
|
Brès JC, Mérieux Y, Dugas V, Broutin J, Vnuk E, Jaber M, Rigal D, Martin JR, Souteyrand E, Cabrera M, Cloarec JP. New Method for DNA Microarrays Development: Applied to Human Platelet Antigens Polymorphisms. Biomed Microdevices 2005; 7:137-41. [PMID: 15940428 DOI: 10.1007/s10544-005-1593-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
DNA microarrays are a powerful experimental tool for the detection of specific genomic sequences and are invaluable to a broad array of applications: clinical diagnosis, personalized medicine, drug research and development, gene therapy, food control technologies, and environmental sciences. Alloimmunization to human platelet antigens (HPAs) is commonly responsible for neonatal alloimmune thrombocytopenia, post-transfusional purpura and platelet transfusion refractoriness. Using DNA microarrays, we developed a diagnosis to type the biallelic HPA-1 platelet group. The region for the human genomic DNA sequence that contains the polymorphism responsible for HPA-1 alleles was amplified by polymerase chain reaction (PCR). The expected DNA fragments were hybridized on DNA microarrays, and the data were analyzed using specially developed software. Our initial results show that the two HPA-1 antigens polymorphisms containing a single base difference were detected using DNA microarrays.
Collapse
Affiliation(s)
- J-C Brès
- LEOM-UMR 5512, Ecole Centrale de Lyon, BP 163, 69131 Ecully Cedex, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Pauchard E, Chiambaretta F, Rouher N, Albertini E, Rigal D. 164 Enophtalmie : à propos d’un cas de « Silent Sinus Syndrome ». J Fr Ophtalmol 2005. [DOI: 10.1016/s0181-5512(05)74560-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Nezzar H, Chiambaretta F, Marceau G, Dastugue B, Rigal D, Sapin V. 043 Analyse moléculaire et métabolique de la voie de signalisation des rétinoïdes au niveau de la surface oculaire humaine. J Fr Ophtalmol 2005. [DOI: 10.1016/s0181-5512(05)74439-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
32
|
Chiambaretta F, Nezzar H, Ferraille L, De graeve F, Marceau G, Elena P, Rigal D, Dastugue B, Sapin V. 380 Variation du niveau des ARNm des krüppel-like factors dans un modèle murin d’angiogénèse cornéenne. J Fr Ophtalmol 2005. [DOI: 10.1016/s0181-5512(05)73501-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Rouher N, Pilon F, Dalens H, Fauquert JL, Kemeny JL, Rigal D, Chiambaretta F. Greffe de membrane amniotique et traitement des ulcères de cornée lors des kératoconjonctivites chroniques allergiques. J Fr Ophtalmol 2004; 27:1091-7. [PMID: 15687918 DOI: 10.1016/s0181-5512(04)96277-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
PURPOSE To determine whether amniotic membrane implantation is a safe and effective alternative treatment for shield ulcers and persistent corneal epithelial defects associated with ulcers in chronic allergic keratoconjunctivitis (vernal or atopic keratoconjunctivitis). METHODS Amniotic membrane implantation was performed in four consecutive patients with persistent corneal epithelial defects or vernal plaques unresponsive to conventional medical treatment lasting an average of 18 weeks. Surgery was done under general anesthesia using amniotic membrane as a therapeutic contact lens. RESULTS A significant decrease in symptoms and complete reepithelialization of the corneal ulcers were observed in all cases within the first 7 days. These remained stable during a mean follow-up of 12 weeks, with no intraoperative or postoperative complications. Early detachment occurred in all cases with no negative consequences on ulcer healing. CONCLUSION Patients with severe chronic allergic keratoconjunctivitis derive benefits from amniotic membrane implantation used as a therapeutic contact lens in the treatment of persistent corneal epithelial defects and vernal plaques unresponsive to conventional medical treatment.
Collapse
Affiliation(s)
- N Rouher
- Service d'Ophtalmologie, Hôpital Gabriel Montpied, CHRU Clermont-Ferrand, Place Henri Dunant, 63000 Clermont-Ferrand Cedex, France.
| | | | | | | | | | | | | |
Collapse
|
34
|
Chiambaretta F, Rozier B, Pilon F, Gérard M, Coulangeon LM, Creveaux I, Rigal D. La photokératectomie thérapeutique dans le traitement de la dystrophie grillagée de type I. J Fr Ophtalmol 2004; 27:747-53. [PMID: 15499271 DOI: 10.1016/s0181-5512(04)96209-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
PURPOSE Lattice corneal dystrophy type I is an autosomal dominant corneal dystrophy caused by allelic mutations of the BIGH3 gene. Type I dystrophy is recognized clinically by the characteristic net of linear opacities within the corneal stroma that results from an accumulation of amyloid. This study was designed to evaluate the therapeutic potential of phototherapeutic keratectomy (PTK) for the treatment of lattice corneal dystrophy type I. PATIENTS AND METHODS PTK was performed with the Chiron Technolas Chiron Keracor 217c on a series of 19 eyes of 13 patients with lattice dystrophy type I. Mean patient age was 38.9 years. The mean follow-up period was 36 months. Localization of central opacities was determined by analyzing Scheimpflug images. The changes in spherical equivalent and best corrected visual acuity were evaluated at 1, 3, 6, 9, 12, 18, 24 and 36 months. RESULTS The central depth of the deposits measured with the Scheimpflug camera was on average 74.14+/-31.03 microm in the primary dystrophies and 30.1+/-10 microm in graft recurrence. We noted a clear improvement in visual acuity, which increased by 0.257+/-0.120 to 0.600+/-0.178 as of the 3rd month and stabilized at 0.684+/-0.257 until the 36th month. A disappearance of repeating ulcerations was observed at month 30. We found a statistically significant correlation (R=0.6776; p=0.0109) between the improvement in vision (in lines) and the depth of opacities (with the Scheimpflug camera). The mean hyperopic shift caused by photoablation (69+/-15 microm) was +0.71+/-1 D at 36 months. CONCLUSION These results confirm that PTK is an effective method of managing corneal lattice dystrophy type I.
Collapse
Affiliation(s)
- F Chiambaretta
- Service d'Ophtalmologie, Hôpital Gabriel Montpied, CHU, Clermont-Ferrand, France
| | | | | | | | | | | | | |
Collapse
|
35
|
Chiambaretta F, Creuzot-Garcher C, Pilon F, Pouliquen P, Rebika H, Dubray C, Rigal D. Intérêt d’une nouvelle formulation de diclofénac sans conservateur pour la surface oculaire. J Fr Ophtalmol 2004; 27:739-44. [PMID: 15499270 DOI: 10.1016/s0181-5512(04)96208-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
AIM To compare the ocular tolerance of nonpreserved diclofenac versus thiomersal-preserved diclofenac in healthy volunteers. MATERIALS AND METHODS Forty healthy volunteers instilled Dicloabak in the randomised eye and thiomersal-preserved diclofenac in the other eye, according to a strictly identical dosing regimen, for 28 days. Each volunteer thus served as his or her own control. The dose regimen was five drops/day for 7 days followed by three drops/day for 20 days. Ocular tolerance was assessed by the discomfort upon instillation (measured on a visual analogue scale [VAS]), subjective ocular symptoms following instillation (irritation/burning/stinging, eye dryness and foreign body sensation) and finally by an objective examination of the ocular surface. These criteria were evaluated on days 0, 14, 21 and 28. RESULTS The subjective ocular symptoms following instillation were significantly lower in the nonpreserved group at Day 7 and nearly significantly lower until the end of the study. The biomicroscopy exam confirmed that there was better tolerance without thiomersal. There was less follicular-papillary conjunctivitis and a significantly better lissamine green score in the Dicloabak group. CONCLUSION The results of this study demonstrate that the nonpreserved formulation of diclofenac is better tolerated by the ocular surface and thus constitutes a therapeutic benefit.
Collapse
Affiliation(s)
- F Chiambaretta
- Service d'Ophtalmologie, CHU de Clermont-Ferrand, Hôpital Gabriel Montpied, Clermont-Ferrand, France
| | | | | | | | | | | | | |
Collapse
|
36
|
Moncharmont P, Dubois V, Obegi C, Vignal M, Mérieux Y, Gebuhrer L, Rigal D. HLA antibodies and neonatal alloimmune thrombocytopenia. Acta Haematol 2004; 111:215-20. [PMID: 15153714 DOI: 10.1159/000077569] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2003] [Accepted: 12/16/2003] [Indexed: 11/19/2022]
Abstract
A female baby with a severe thrombocytopenia at 18 x 10(9)/l was born to a 29-year-old (gestation 2/partum 2) mother. Scattered petechiae were present on her legs, arms, chest and face, but there was no bleeding, infection, fever or hepatosplenomegaly. A platelet antibody screening immunocapture test was positive, which was performed on the mother's serum 3, 12 and 38 days after delivery, but no platelet-specific antibodies were found by the monoclonal-antibody-specific immobilization of platelet antigen assay. The baby's platelets and lymphocytes and the father's platelets reacted strongly with the HLA antibodies present in the mother's serum. The neonate was treated with intravenous human immunoglobulin (Tegeline), 1 g/kg per day) 1, 2 and 3 days after delivery. The platelet count rose from 18 x 10(9)/l on day 0 to 37 x 10(9)/l on day 3 and to 227 x 10(9)/l on day 12. No platelet transfusion was needed. Several factors which developed hereafter lead us to think that this neonatal alloimmune thrombocytopenia is due to the transplacental passage of maternal HLA antibodies to the baby.
Collapse
Affiliation(s)
- P Moncharmont
- Etablissement français du Sang, Rhône-Alpes Site de Lyon, Lyon, France.
| | | | | | | | | | | | | |
Collapse
|
37
|
Chiambaretta F, Pilon F, Deriot JB, Gerard M, Couleangon ML, Schorderet DF, Kemeny JL, Dastugue B, Creveaux I, Rigal D. Récidive d’une dystrophie de Groenouw de type I après photokératectomie thérapeutique. J Fr Ophtalmol 2004; 27:449-56. [PMID: 15179300 DOI: 10.1016/s0181-5512(04)96164-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
PURPOSE Granular corneal dystrophy Groenouw type 1 (GGI) is a rare autosomal dominant disease caused by allelic mutations of the BIGH3 gene. The specific phenotype is characterized by granular opacities (white, sharply demarcated spots resembling bread crumbs) in corneal stroma, which cause recurrent corneal erosions and blurred vision. Phototherapeutic keratectomy (PTK) is an effective procedure that improves visual acuity, but recurrences are unavoidable. Though GGI deposits are well described, their origin is not completely known. The production of mutated keratoepithelin protein (a product of the BIGH3 gene) is the first step necessary for deposits to appear. Molecular biology experiments were conducted to determine the role of corneal cell types in the genesis of early recurrent deposits of post-PTK GGI. METHODS Tissue specimens from a patient undergoing penetrating keratoplasty for recurrence of GGI (12 months after PTK) and five normal corneas were examined by hybridization in situ and immunohistology to study the expression of BIGH3 and location of keratoepithelin. RESULTS Only one healthy cornea expressed BIGH3 mainly in the epithelium and less in keratinocytes and endothelial cells. In the GGI corneas, BIGH3 was highly expressed in the modified, hyperplastic epithelium. The keratoepithelin was accumulated under the epithelium where deposits were formed. CONCLUSION This observation confirms that corneal epithelium is the main producer of mutated keratoepithelin on the cellular scale and thus constitutes the principal source of dystrophic deposit formation during recurrence.
Collapse
Affiliation(s)
- F Chiambaretta
- Service d'Ophtalmologie, Hôpital Gabriel Montpied, BP 69, Clermont-Ferrand cedex, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Chiambaretta F, Pouliquen P, Menerath JM, Pilotaz F, Rebika H, Rigal D. Efficacité et tolérance d’un gel de carbomère fluide versus un gel de carbomère classique lors du traitement du syndrome sec. J Fr Ophtalmol 2004; 27:130-5. [PMID: 15029039 DOI: 10.1016/s0181-5512(04)96106-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
AIM To compare the risk/benefit for C974P (a 0.25% fluid carbomer gel in a vial allowing dropwise instillation) versus a conventional carbomer gel. MATERIAL AND METHODS During this multicenter, randomized, investigator-masked trial, patients with dry eye syndrome were treated with C974P or C940. Control visits were planned on day 7, day 28 (efficacy evaluation) and day 56 (tolerance evaluation). The main criterion was dry eye symptoms globally assessed by a visual analog scale (VAS). The non-inferiority limit for the between-group difference of VAS changes was 10 mm. RESULTS In the population of 169 patients (87 patients for C974P, 82 for C940), C974P was at least as effective as C940 on symptoms (non-inferiority hypothesis confirmed). The mean VAS value fell by one third in the two groups. The objective signs improved identically in the two groups: corneal staining by fluorescein (p=0.96), rose Bengal score (p=0.73), and lacrimal break-up time (p=0.73). The dosage adaptation was slightly lower than three instillations per day (p=0.16). The adverse events were mild or moderate. CONCLUSION C974P galenic changes are able to reach the same level of efficacy on dry eye symptoms and ocular surface damages as the conventional tube carbomer gels.
Collapse
Affiliation(s)
- F Chiambaretta
- Service d'Ophtalmologie, CHU Gabriel Montpied, 28, Place Henri Dunant, BP 69, 63003 Clermont-Ferrand
| | | | | | | | | | | |
Collapse
|
39
|
Buc D, Pilon F, Donnarieix D, Kemeny JL, Bacin F, Rigal D. [Treatment of conjunctival epithelial tumors: brachytherapy with ruthenium-106]. J Fr Ophtalmol 2003; 26:929-39. [PMID: 14631277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
INTRODUCTION Treatment of conjunctival epithelial tumors is not standardized because it is difficult to compare large series in this rare disease. Surgical excision is usual, but the recurrence rate has led several authors to propose alternative therapies. PATIENTS AND METHODS During the past 20 years, brachytherapy using ophthalmic applicators has been developed and the results of different studies have confirmed the usefulness of this therapy. We report a retrospective study of 13 patients presenting with a conjunctival epithelial tumor treated with ruthenium106 applicators and followed up in our department since 1987. RESULTS AND CONCLUSION There was no recurrence during a mean follow-up of 48 months. Complications depended on the size of the area treated and the dose of radiation.
Collapse
Affiliation(s)
- D Buc
- Service d'Ophtalmologie, Hôpital G. Montpied, CHU de Clermont-Ferrand
| | | | | | | | | | | |
Collapse
|
40
|
Bron A, Chiambaretta F, Pouliquen P, Rigal D, Rouland JF. [Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension]. J Fr Ophtalmol 2003; 26:668-74. [PMID: 13130253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/05/2023]
Abstract
AIM To evaluate the efficacy and safety of a single daily instillation of nonpreserved timolol in patients with chronic glaucoma or ocular hypertension previously treated with a twice-daily regimen of timolol 0.25% or 0.50%. PATIENTS AND METHODS A prospective open clinical trial was undertaken by 220 ophthalmologists in 435 patients with chronic glaucoma or ocular hypertension controlled with twice-daily instillations of timolol 0.25% or 0.50%. In this population, the previous regimen was substituted with a single daily instillation of preservative-free timolol 0.25% or 0.50% for 3 months. The changes in intraocular pressure (IOP) were recorded as well as local and systemic tolerance and patient compliance. RESULTS It was found that 398 patients (93.6%) maintained stable IOP: in 92%, IOP increased no more than 2 mmHg. The mean IOP was 17.0 +/- 2.2 mmHg at D0, 16.5 +/- 2.4 mmHg at D28/42 and 16.6 +/- 2.4 mmHg at D84. The proportion of patients with at least one ocular symptom upon instillation or at another time decreased (p<0.0001 and p=0.03, respectively). The proportion of conjunctival hyperemia reduced from 24.4% to 14.6% (p=0.0002). The rate of folliculopapillar reactions and superficial punctate keratitis was halved (p=0.005 and p=0.02, respectively). CONCLUSION During this study in daily practice, the switch from a twice-daily regimen of timolol to a once-daily application maintained stable intraocular pressure with a notable improvement in tolerance.
Collapse
Affiliation(s)
- A Bron
- Service d'Ophtalmologie, CHU de Dijon, Hôpital Général, 3, rue du Faubourg Raines, BP 1519, 21033 Dijon Cedex.
| | | | | | | | | |
Collapse
|
41
|
Moncharmont P, Plantier A, Chirat V, Rigal D. ABO and Rh(D) blood typing on the PK 7200 with ready-to-use kits. Immunohematology 2003; 19:54-6. [PMID: 15373695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
The performance of ready-to-use kits was evaluated on the PK 7200 blood grouping system. The Olymp Group (kit 1) and Olymp Group II (kit 2) containing anti-A, -B, -AB, and -D reagents were tested for first and second determinations of A, B, and D antigens. More than 500 RBC samples, including several variant ABO and D phenotypes, were evaluated for specificity, repeatability, reproducibility, and sensitivity. Specificity was tested with well-characterized reagent RBCs. Repeatability was established by at least 12 assays per run with three reagent RBCs, and reproducibility was established on one run per day for 5 days. No discrepancy was observed in ABO and D determinations with either kit. In repeatability, three discrepancies were found with group A and B RBCs with kit 1. In reproducibility, no discrepancies were observed. The kit 1 anti-A reagent detected A3 but not Ax RBCs and anti-AB detected both. A B3 RBC was detected by both kits. Among eight weak D phenotypes, six were positive with kit 1. With kit 2, only one of five weak D phenotypes was detected.
Collapse
Affiliation(s)
- P Moncharmont
- Department of Immunology, E.F.S. Rhône-Alpes Site de Lyon, 1-3 rue du Vercors, 69364 Lyon cedex 07 France
| | | | | | | |
Collapse
|
42
|
Duperrier K, Farre A, Bienvenu J, Bleyzac N, Bernaud J, Gebuhrer L, Rigal D, Eljaafari A. Cyclosporin A inhibits dendritic cell maturation promoted by TNF‐α or LPS but not by double‐stranded RNA or CD40L. J Leukoc Biol 2002. [DOI: 10.1189/jlb.72.5.953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- K. Duperrier
- Departments of Cell Therapy, Immunology, HLA Clinical Pharmacology, Etablissement Français du Sang région Rhone‐Alpes, site de Lyon, Centre Hospitalier Lyon‐Sud, and Hopital Debrousse, France, Jeune equipe universitaire, 2267, UCLB, France
| | - A. Farre
- Departments of Cell Therapy, Immunology, HLA Clinical Pharmacology, Etablissement Français du Sang région Rhone‐Alpes, site de Lyon, Centre Hospitalier Lyon‐Sud, and Hopital Debrousse, France, Jeune equipe universitaire, 2267, UCLB, France
| | - J. Bienvenu
- Departments of Cell Therapy, Immunology, HLA Clinical Pharmacology, Etablissement Français du Sang région Rhone‐Alpes, site de Lyon, Centre Hospitalier Lyon‐Sud, and Hopital Debrousse, France, Jeune equipe universitaire, 2267, UCLB, France
| | - N. Bleyzac
- Departments of Cell Therapy, Immunology, HLA Clinical Pharmacology, Etablissement Français du Sang région Rhone‐Alpes, site de Lyon, Centre Hospitalier Lyon‐Sud, and Hopital Debrousse, France, Jeune equipe universitaire, 2267, UCLB, France
| | - J. Bernaud
- Departments of Cell Therapy, Immunology, HLA Clinical Pharmacology, Etablissement Français du Sang région Rhone‐Alpes, site de Lyon, Centre Hospitalier Lyon‐Sud, and Hopital Debrousse, France, Jeune equipe universitaire, 2267, UCLB, France
| | - L. Gebuhrer
- Departments of Cell Therapy, Immunology, HLA Clinical Pharmacology, Etablissement Français du Sang région Rhone‐Alpes, site de Lyon, Centre Hospitalier Lyon‐Sud, and Hopital Debrousse, France, Jeune equipe universitaire, 2267, UCLB, France
| | - D. Rigal
- Departments of Cell Therapy, Immunology, HLA Clinical Pharmacology, Etablissement Français du Sang région Rhone‐Alpes, site de Lyon, Centre Hospitalier Lyon‐Sud, and Hopital Debrousse, France, Jeune equipe universitaire, 2267, UCLB, France
| | - A. Eljaafari
- Departments of Cell Therapy, Immunology, HLA Clinical Pharmacology, Etablissement Français du Sang région Rhone‐Alpes, site de Lyon, Centre Hospitalier Lyon‐Sud, and Hopital Debrousse, France, Jeune equipe universitaire, 2267, UCLB, France
| |
Collapse
|
43
|
Duperrier K, Farre A, Bienvenu J, Bleyzac N, Bernaud J, Gebuhrer L, Rigal D, Eljaafari A. Cyclosporin A inhibits dendritic cell maturation promoted by TNF-alpha or LPS but not by double-stranded RNA or CD40L. J Leukoc Biol 2002; 72:953-61. [PMID: 12429717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
Abstract
Here, we investigated the influence of cyclosporin A (CsA) on dendritic cell (DC) generation. With this aim, human DC were propagated from monocytes in serum-free medium with granulocyte macrophage-colony stimulating factor and interleukin-4. DC were then exposed to tumor necrosis factor alpha (TNF-alpha) for maturation. Our results show that CsA does not impair commitment of monocytes into DC, as assessed by loss of CD14 and increase of CD40 and CD1a. However, TNF-alpha-induced DC maturation was affected, as CsA-treated DC expressed lower levels of human leukocyte antigen and costimulatory molecules but sustained levels of CD1a, and less DC expressed DC-lysosomal-associated-membrane-protein (LAMP) and CD83. Accordingly, CsA inhibited the allostimulatory and accessory cell functions of DC. Surprisingly, when other maturation stimuli were used, we observed that CsA significantly inhibited maturation induced by lipopolysaccharides but not by polyribocytidylic acid or CD40 ligand, as assessed by DC phenotype and functions. Therefore, our results indicate that CsA may differentially affect DC maturation.
Collapse
Affiliation(s)
- K Duperrier
- Department of Cell Therapy, HLA Clinical Pharmacology, Etablissement Français du Sang région Rhone-Alpes, site de Lyon, Centre Hospitalier Lyon-Sud, and Hopital Debrousse, France
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Guyot B, Arnaud S, Phothirath P, Bourette RP, Grasset MF, Rigal D, Mouchiroud G. Genomic organization and restricted expression of the human Mona/Gads gene suggests regulation by two specific promoters. Gene 2002; 290:173-9. [PMID: 12062812 DOI: 10.1016/s0378-1119(02)00555-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Monocytic adaptor (Mona) also known as Gads is a Grb2-related adaptor whose expression is restricted to hematopoietic cells. It plays an important role in intracellular signaling in T cells, monocytic cells, and platelets. Here we investigated the regulatory aspects of Mona expression in human hematopoietic cells. This was carried out by combining nucleotide sequence analyzes and experimental approaches. We confirmed that Mona expression is restricted to T-cell, myeloid and platelet lineages. In the various cells examined, we detected two major Mona transcripts (1.9 and 4 kb), likely resulting from the alternative use of two polyadenylation sites. Consequently, Mona transcripts of the same size have identical 3' untranslated region (UTR), irrespective of the cell type. In contrast, Mona transcripts contain either 5' UTR-1A or -1B exons, that were detected in a cell-lineage specific manner. Thus, T cells and several myeloid cell lines express 5' UTR-1A-containing transcripts, whereas platelets and cell lines exhibiting megakaryocytic potential express 5' UTR-1B-containing transcripts. Interestingly, 5' UTR-1A is generated from an exon located approximately 45 kb upstream of exon 1B. This suggested that lineage-restricted transcription of the Mona gene is controlled by specific promoters. Indeed, 2-kb genomic fragments upstream of each 5'-UTR showed lineage-restricted ability to drive expression of luc reporter gene.
Collapse
Affiliation(s)
- B Guyot
- Centre de Génétique Moléculaire et Cellulaire, UMR CNRS 5534, Université Claude Bernard Lyon-1, Bâtiment Gregor Mendel, 16 rue Raphael Dubois, Villeurbanne Cedex, France
| | | | | | | | | | | | | |
Collapse
|
45
|
Aouacheria A, Arnaud E, Venet S, Lalle P, Gouy M, Rigal D, Gillet G. Nrh, a human homologue of Nr-13 associates with Bcl-Xs and is an inhibitor of apoptosis. Oncogene 2001; 20:5846-55. [PMID: 11593390 DOI: 10.1038/sj.onc.1204740] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2001] [Revised: 06/11/2001] [Accepted: 06/18/2001] [Indexed: 11/08/2022]
Abstract
In search of human homologues of the anti-apoptotic protein Nr-13, we have characterized a human EST clone that potentially encodes a protein, which is the closest homologue of Nr-13 among the Bcl-2 family members, to date known, in humans. Phylogenetic analyses suggest Human nrh, Mouse diva/boo and Quail nr-13 to be orthologous genes. The nrh gene has the same overall organization as nr-13 and diva/boo with one single intron interrupting the ORF at the level of the Bcl-2-homology domain BH2. RT-PCR-based analysis of nrh expression indicated that this gene is preferentially expressed in the lungs, the liver and the kidneys. Interestingly, two in frame ATG codons can lead potentially to the synthesis of two products, one of them lacking 10 aminoacids at the N-terminal end. Sequence alignment with Nr-13 and Diva/Boo in addition to secondary structure prediction of the nrh transcript suggested that the shortest protein will be preferentially synthetized. Immunohistochemical analyses have revealed that Nrh is associated with mitochondria and the nuclear envelope. Moreover, Nrh preferentially associates with the apoptosis accelerator Bcl-Xs and behaves as an inhibitor of apoptosis both in yeast and vertebrate cells.
Collapse
Affiliation(s)
- A Aouacheria
- Institut de Biologie et Chimie des Protéines, UMR 5086 CNRS/Université Claude Bernard, 7 passage du Vercors, F69367 Lyon cedex 07, France
| | | | | | | | | | | | | |
Collapse
|
46
|
Eljaafari A, Farre A, Duperrier K, Even J, Vie H, Michallet M, Souillet G, Catherine Freidel A, Gebuhrer L, Rigal D. Generation of helper and cytotoxic CD4+T cell clones specific for the minor histocompatibility antigen H-Y, after in vitro priming of human T cells by HLA-identical monocyte-derived dendritic cells. Transplantation 2001; 71:1449-55. [PMID: 11391234 DOI: 10.1097/00007890-200105270-00016] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND There is now convincing evidence that minor histocompatibility antigens (mHag) may play a significant role in the pathogenesis of graft-versus-host disease after HLA-identical bone marrow transplantation. Indeed, in this clinical situation, T cells specific for mHag have been isolated. Here, we addressed whether one can generate mHag-specific T cells in vitro, without any in vivo immunization, among healthy blood donors. METHODS We used monocyte-derived dendritic cells (Mo-DCs) as antigen presenting cells to induce primary responses between healthy HLA-identical siblings, in mixed lymphocyte dendritic cell reactions (MLDCRs). RESULTS We show that CD4+ T-cell clones, specific for the mHag H-Y, can be generated in vitro. These clones were derived from a gender-mismatched positive MLDCR pair of HLA-identical siblings and were restricted by the HLA DQB1*0502 molecule. In addition, these CD4+ T clones were also able to lyse allogeneic targets with the same pattern of restriction and specificity than helper function. Finally, acute myeloid leukemia (AML) blast cells were susceptible to lysis by these clones. CONCLUSIONS Altogether, these results predict that Mo-DCs could help to generate class II-associated, mHag-specific, T-cell lines or clones in vitro, between healthy blood donors, without any need of transplantation-mediated immunization.
Collapse
Affiliation(s)
- A Eljaafari
- Banque de Tissus et Cellules, Pavillon I, Hopital E. Herriot, 5 place d'Arsonval, 69003 Lyon, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Chabanne L, Bonnefont C, Bernaud J, Rigal D. Clinical applications of flow cytometry and cell immunophenotyping to companion animals (dog and cat). Methods Cell Sci 2001; 22:199-207. [PMID: 11264954 DOI: 10.1023/a:1009800310840] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Clinical applications of flow cytometry to certain diseases of the dog and cat are now possible. The utility of such applications for diagnosis, prognosis and follow-up are illustrated here by a number of examples: feline AIDS resulting from FIV infection, Leukocyte Adhesion Deficiency in Irish setters, deep pyoderma in German shepherds, Immune-mediated Thrombocytopenia, canine Systemic Lupus Erythematosus and Leishmaniasis, Leukemia and Lymphoma.
Collapse
Affiliation(s)
- L Chabanne
- Médecine interne - Département des Animaux de Compagnie, Ecole Nationale Vétérinaire de Lyon, BP 83, 69 280 Marcy L'Etoile, France
| | | | | | | |
Collapse
|
48
|
Chabanne L, Ponce F, Ghernati I, Goy-Thollot I, Cadoré JL, Rigal D, Fournel C. A canine granular lymphocyte proliferative disease without an aggressive clinical course. J Vet Intern Med 2001; 15:249-51. [PMID: 11380035 DOI: 10.1892/0891-6640(2001)015<0249:acglpd>2.3.co;2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Affiliation(s)
- L Chabanne
- Department of Companion Animals, Ecole Nationale Vétérinaire de Lyon, Marcy L'Etoile, France. l,
| | | | | | | | | | | | | |
Collapse
|
49
|
Mabrut JY, Adham M, Bourgeot JP, Eljaafari A, DelaRoche E, Ducerf C, Baulieux J, Rigal D. Mechanical and histological characteristics of human trachea before and after cryopreservation: an opportunity for tracheal tissue banking. Transplant Proc 2001; 33:609-11. [PMID: 11266982 DOI: 10.1016/s0041-1345(00)02166-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- J Y Mabrut
- Department of Surgery and Transplantation, Croix-Rousse Hospital, Lyon, France
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Leitienne P, Fouque D, Rigal D, Adeleine P, Trzeciak MC, Laville M. Heparins and blood polymorphonuclear stimulation in haemodialysis: an expansion of the biocompatibility concept. Nephrol Dial Transplant 2000; 15:1631-7. [PMID: 11007833 DOI: 10.1093/ndt/15.10.1631] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND At the concentrations used in haemodialysis and in a dose-dependent way, unfractionated heparin (UFH) and, to a lesser degree, a low-molecular-weight heparin (LMWH) stimulate polymorphonuclear cells (PMN) in vitro, and could act in synergy with the stimulatory effect of dialysis membranes in vivo. To examine this hypothesis, we studied the effects of different heparin types and regimens on blood PMNs during haemodialysis sessions. METHODS Ten haemodialysed patients were studied during regular dialysis sessions on a cellulose triacetate membrane (CT 110 G; 1.10 m(2); Baxter), with four different random heparin protocols: one high-UFH regimen (HHR) at 90 IU/kg body-weight (b.w.) and one low-UFH regimen (LHR) at 50 IU/kg b.w., and with a LMWH (nadroparin calcium) at 85 (HHR) or 45 (LHR) IU/kg b.w. Blood granulocytes, platelet counts, and plasma granulocyte degranulation products (elastase, lactoferrin) were measured serially during 4 h dialysis sessions. RESULTS After 10 min, the reduction in PMNs with UFH was 29.5% for HHR (P<0.01) and 28.5% for LHR (P<0.01), and only 16.8 and 18.6% with LMWH (NS), significantly higher for HHR with UFH than with LMWH (P<0.01). At 60 min, the elastase increase with HHR was greater, 61% with UFH (P<0.01) and 37.8% with LMWH (P<0.01), significantly higher than LHR for UFH (P<0.05) or LMWH (P<0.05). The overall decrease in platelets (with LMWH P<0.01) and the overall increase in lactoferrin (P<0.001) were not different between heparinization procedures. CONCLUSION Under a conventional heparin regimen, the PMN variation during the course of the dialysis session suggests a more biocompatible effect of LMWH over UFH. In addition, the variation of elastase favours the lower dose, whatever the type of heparin. Heparin type and dose should therefore be considered in studies addressing biocompatibility in haemodialysis: a low dose of LMWH may be viewed as a better biocompatible treatment with regard to leukocyte stimulation.
Collapse
Affiliation(s)
- P Leitienne
- Centre d'Hémodialyse, Hôpital P. Wertheimer, et département de Néphrologie, Hôpital Edouard Herriot, Lyon, France
| | | | | | | | | | | |
Collapse
|